# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

# B. Purpose for Submission:

Notification of intent to manufacture and market the device: Microalbumin TIA reagent, calibrator set and controls

C. Measurand: Microalbumin

D. Type of Test: Quantitative, turbidometric immunoassay

E. Applicant: Good Biotech Corporation

F. Proprietary and Established Names:

Proprietary Names

Microalbumin TIA Reagent mAlb Calibrator Set 200 mAlb Control-L, Control-H

Established Names

Urinary albumin immunological test system   
Urinary albumin calibrator   
Urinary albumin controls

# G. Regulatory Information:

1. Regulation section:

Microalbumin TIA Reagent - 21 CFR 866.5040   
mAlb Calibrator Set 200 - 21 CFR 862.1150

2. Classification:

Microalbumin TIA Reagent – Class II (Special Controls) This device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to 866.9 subpart (c) (5).   
mAlb Calibrator Set 200 – Class II   
mAlb Control-L, Control-H – Class I

3. Product code:

Microalbumin TIA Reagent - DDZ mAlb Calibrator Set 200 - JIT mAlb Control-L, Control-H - JJX

4. Panel:

Microalbumin TIA Reagent 81 Immunology mAlb Calibrator Set 200 75 Chemistry mAlb Control-L, Control-H 75 Chemistry

# H. Intended Use:

1. Intended use(s): Please see indications for use below

2. Indication(s) for use:

Good Biotech Corp. (GBC) Microalbumin test system is intended to be used for the quantitative determination of low level albumin in human urine by turbidometric immunoassay (TIA). Measurement of albumin aids in the diagnosis of kidney disease.

GBC mAlb Calibrator Set 200 is intended to be used with GBC Microalbumin TIA for the quantitative determination of microalbumin in urine samples.

GBC Microalbumin Controls are to be used as the assayed quality control material for the urinary albumin analysis.

For In Vitro Diagnostic Use

3. Special conditions for use statement(s): For professional use only

4. Special instrument requirements:

Microalbumin TIA is a “ready to use” reagent kit for clinical chemistry autoanalyzers. Microalbumin TIA has been tested on the Hitachi 911 Clinical Chemistry analyzer.

# I. Device Description:

Microalbumin TIA consists of a “ready to use” reagent kit - Reagent 1 (reactive buffer solution) and Reagent 2 (antibody solution) in a one kit set. The antibody consists of a duck anti-albumin from purified duck yolk. The host ducks are domestic stock and are inoculated to prevent avian associated diseases.

The calibrators consist of 5 levels of albumin in ${ } ^ { 2 \mathsf { m L } }$ bottles. They are provided in liquid form. The calibrators are prepared from human sera which were found to be negative for HbsAg, anti-HIV1 and 2 antibodies and antiHCV antibody.

The controls consist of 2 levels of albumin in $1 . 5 \mathsf { m L }$ bottles. They are provided in liquid form. The controls are prepared from human sera which were found to be negative for HbsAg, anti-HIV1 and 2 antibodies and antiHCV antibody by FDA licensed methods.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Randox Microalbumin Test kit, Wako Micro-Albumin B/Wako Micro Albumin Calibrator

2. Predicate 510(k) number(s): k002674, k944664

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=2>Predicate</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>Microalbumin TIAmAlb Calibrator Set 200mAlb Control-L, Control-H</td><td rowspan=1 colspan=1>Randox Microalbumin Test kit</td><td rowspan=1 colspan=1>Wako Micro-Albumin B/Wako Micro AlbuminCalibrator</td></tr><tr><td rowspan=1 colspan=4>Reagent</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>For the quantitative in vitrodetermination of Microalbuminin urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Turbidimetric ImmunoAssay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=1>Reactive Buffer Solution(R1):Tris bufferAntibody Solution (R2):Duck anti-human albuminantibody</td><td rowspan=1 colspan=1>Assay Buffer:PEG, Tris/HCl buffer, NaClAntibody Reagent:Anti-human albumin, Tris/HClbuffer, NaCl</td><td rowspan=1 colspan=1>Buffer:Good&#x27;s buffer, NaN3Antibody B:Rabbit anti-human albuminantibody, mouse anti-humanalbumin antibody, NaN3</td></tr><tr><td rowspan=1 colspan=1>SampleVolume</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>20 μl/test</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ReagentVolume</td><td rowspan=1 colspan=1>R1 : 250 μl/testR2: 30 μl/test</td><td rowspan=1 colspan=1>Assay Buffer: 250 μl/testAntibody Reagent: 25 μl/test</td><td rowspan=1 colspan=1>Buffer: 300 μl/testAntibody B: 100 μl/test</td></tr><tr><td rowspan=1 colspan=1>Wavelength</td><td rowspan=1 colspan=1>Main/sub:340 nm/ 700 nm</td><td rowspan=1 colspan=1>Main/sub:340 nm/-</td><td rowspan=1 colspan=1>Main/sub:340 nm/ 700 nm</td></tr><tr><td rowspan=1 colspan=1>Interference</td><td rowspan=1 colspan=1>No interference to:ascorbic acid (250 mg/dL),glucose (10000 mg/dL), urea(4000 mg/dL), uric acid (100mg/dL), creatine (50 mg/dL),creatinine (2000 mg/dL),urobilinogen (20 mg/dL),bilirubin (30 mg/dL),hemoglobin (300 mg/dL), IgG(50 mg/dL), calcium (75mg/dL), magnesium (75mg/dL), inorganic phosphorus(50 mg/dL), potassium chloride(2000 mg/dL), sodium chloride(2000 mg/dL), chloroform(1000 μg/dL), toluene (1000μg/dL), xylene (1000 μg/dL),thymol (50000 μg/dL) andformalin (750 μg/dL)</td><td rowspan=1 colspan=1>No interference to:ascorbic acid (4 g/1), bilirubin(250 mg/l), creatinine (4 g/l),gentamicin (10 g/1), glucose(40 g/l), paracetemol (5 g/l),potassium chloride (10 g/1),sodium chloride (20 g/1), urea(40 g/l)</td><td rowspan=1 colspan=1>No interference to:ascorbic acid (400 mg/dL),glucose (4000 mg/dL), uricacid (100 mg/dL), urea (400mg/dL), creatinine (400mg/dL), sodium chloride (2000mg/dL), potassium chloride(1000 mg/dL), calcium (100mg/dL), inorganic phosphorus(400 mg/dL), hippuric acid(400 mg/dL), hemoglobin (500mg/dL), bilirubin (25 mg/dL),urobilinogen (20 mg/dL), 6Nhydrochloric acid (4 mL/dL),toluene (1000 μg/dL), xylene(1000 μg/dL), chloroform(1000μg/dL), formalin (1000μg/dL), acetic acid (1000μg/dL)</td></tr><tr><td rowspan=1 colspan=2>Ca</td><td rowspan=1 colspan=2>Calibrator/ Control</td></tr><tr><td rowspan=1 colspan=1>Target Analyte</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Human serum albumin</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Preservative</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Sodium Azide</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Preparation</td><td rowspan=1 colspan=1>Calibrator: liquid (ready-to-useControl: liquid (ready-to-use)</td><td rowspan=1 colspan=1>Calibrator: liquid (ready-to-useControl: powder (reconstitutionby redistilled water)</td><td rowspan=1 colspan=1>Calibrator: liquid (ready-to-use</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Guidance for Industry - Abbreviated 510(k) Submissions for In Vitro Diagnostic Calibrators; Final FOD 1247

Guidance for Industry and FDA Staff; Replacement Reagent and Instrument

Family Policy FOD 950

# Shelf Life of Medical Devices FOD 415

CLSI document EP14-A Evaluation of Matrix Effects; Approved Guidelines.

L. Test Principle: Immunoturbidometric

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

With-in run precision was established by assaying 2 samples for 20 times. The results are as follows:

Within-run precision   

<table><tr><td rowspan=1 colspan=1>Sample #</td><td rowspan=1 colspan=1>Replicates</td><td rowspan=1 colspan=1>Mean (mg/L)</td><td rowspan=1 colspan=1>S.D.</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>18.77</td><td rowspan=1 colspan=1>0.385</td><td rowspan=1 colspan=1>2.049</td></tr><tr><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>57.28</td><td rowspan=1 colspan=1>1.029</td><td rowspan=1 colspan=1>1.797</td></tr></table>

Total precision was established by assaying 2 samples in duplicate twice a day for 20 days. The results are as follows:

Total Precision   

<table><tr><td rowspan=1 colspan=1>Number ofAssayDays</td><td rowspan=1 colspan=1>Mean(mg/L)</td><td rowspan=1 colspan=1>S.D.</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>Swr</td><td rowspan=1 colspan=1>ST</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20.56</td><td rowspan=1 colspan=1>1.431</td><td rowspan=1 colspan=1>6.96</td><td rowspan=1 colspan=1>0.598</td><td rowspan=1 colspan=1>1.804</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>45.28</td><td rowspan=1 colspan=1>2.132</td><td rowspan=1 colspan=1>4.71</td><td rowspan=1 colspan=1>0.699</td><td rowspan=1 colspan=1>2.872</td></tr></table>

b. Linearity/assay reportable range:

Linearity was established using a range of dilutions from a $2 0 0 ~ \mathrm { { m g / L } }$ albumin urine sample. The ${ \mathsf { R } } ^ { 2 }$ value obtained from the linear regression was 0.9966. Linearity was established from 0 to $2 0 0 ~ \mathrm { { m g / L } }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The assigned albumin values of the GBC mAlb calibrator set 200 and

GBC Microalbumin Controls are determined by the turbidometric immunoassay and are traceable to the IFCC/BCR/CAP reference material CRM 470.

The accelerated stability studies were performed to predict the shelf life of mAlb set 200 and Microalbumin controls under recommended storage conditions. The studies were conducted according to FDAdocumented Shelf Life of Medical Devices, FOD 415.

Stability was determined to be 28 days after opening if stored at ${ 2 ^ { \circ } \mathsf C }$ to $1 0 ^ { \circ } \mathsf { C }$ . Stability unopened was determined to be 9 months when stored at recommended conditions.

Reagent R1 and R2 are stabile up to the expiration date if stored at ${ 2 ^ { \circ } \mathsf { C } }$ to $1 0 ^ { \circ } \mathsf { C }$ . R1 and R2 are stabile opened and refrigerated at ${ 2 ^ { \circ } \mathsf { C } }$ to $1 0 ^ { \circ } \mathsf { C }$ for 30 days.

# d. Detection limit:

The detection limit $0 . 3 \ : \mathrm { m g / L }$ was calculated as 2SD above the mean response of the zero calibrator when assayed 20 times.

# e. Analytical specificity:

Interference was defined as above $10 \%$ difference with original assay values. Interferents with the following concentrations did not interfere with Microalbumin TIA.

<table><tr><td>Formalin</td><td>750 μg/dL</td><td>Uric Acid</td><td>100 mg/dL</td></tr><tr><td>Thymol</td><td>50000 μg/dL</td><td>Creatine</td><td>200 mg/dL</td></tr><tr><td>Chloroform</td><td>1000 μg/dL</td><td>Creatinine</td><td>2000 mg/dL</td></tr><tr><td>Toluene</td><td>1000 μg/dL</td><td>Calcium</td><td>75 mg/dL</td></tr><tr><td>Xylene</td><td>1000 μg/dL</td><td>Inorganic Phosphorous</td><td>75 mg/dL</td></tr><tr><td>Potassium Chloride</td><td>2000 mg/dL</td><td>IgG</td><td>50 mg/dL</td></tr><tr><td>Sodium Chloride</td><td>2000 mg/dL</td><td>Magnesium</td><td>75 mg/dL</td></tr><tr><td>Ascorbic Acid</td><td>250 mg/dL</td><td>Urobilinogen</td><td>20 mg/dL</td></tr><tr><td>Glucose</td><td>10000 mg/dL</td><td>Hemoglobin</td><td>300 mg/dL</td></tr><tr><td>Urea</td><td>4000 mg/dL</td><td>Bilirubin</td><td>30 mg/dL</td></tr></table>

f. Assay cut-off:

Not Applicable

# 2. Comparison studies:

a. Method comparison with predicate device:

50 leftover urine samples were collected. Since extensive patient data was not required in the study, no name or linked identification number linked with the leftover samples was provided. Microalbumin measurements were performed on each sample in duplicate. Each sample was also tested using the predicate devices according to the manufacturer’s instructions. Testing was performed on the Roche Diagnostics Hitachi 911 analyzer. The results of regression are shown on the table below:

<table><tr><td rowspan=1 colspan=1>Test Method</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Y intercept</td><td rowspan=1 colspan=1>$R^{2} value</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>PredicateMethod</td></tr><tr><td rowspan=1 colspan=1>MicroalbuminTIA</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>-0.56 mg/L</td><td rowspan=1 colspan=1>0.997</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>RandoxMicroalbumin</td></tr><tr><td rowspan=1 colspan=1>MicroalbuminTIA</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>-2.17 mg/L</td><td rowspan=1 colspan=1>0.998</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>Wako Micro-Albumin B</td></tr></table>

b. Matrix comparison: Not Applicable

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable

b. Clinical specificity: Not Applicable

c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable

4. Clinical cut-off: Not Applicable

# 5. Expected values/Reference range:

Reference Intervals 24 – h collection: less than $3 0 \mathrm { m g } / 2 4$ hour Timed collection: less than $2 0 \mu \ g / \mathrm { m i n }$ Spot collection: less than 30mg/g creatinine

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.